ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000110

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

Identifieur interne : 000110 ( PascalFrancis/Corpus ); précédent : 000109; suivant : 000111

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

Auteurs : Roger S. Mcintyre ; Alissa M. Powell ; Oksana Kaidanovich-Beilin ; Joanna K. Soczynska ; Mohammad Alsuwaidan ; Hanna O. Woldeyohannes ; Ashley S. Kim ; L. Ashley Gallaugher

Source :

Behavioural brain research [ 0166-4328 ] ; 2013.

RBID : Pascal:13-0122012

Descripteurs français

Pascal (Inist)
- Neuroprotection, Traitement, Trouble cognitif, Trouble de l'humeur, Cognition, Incrétine.

English descriptors

KwdEn :
- Cognition, Cognitive disorder, Incretin, Mood disorder, Neuroprotection, Treatment.

Abstract

Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-4328`
A02	`01`			`@0 BBREDI`
A03		`1`		`@0 Behav. brain res.`
A05				`@2 237`
A08	`01`	`1`	`ENG`	`@1 The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders`
A11	`01`	`1`		`@1 MCINTYRE (Roger S.)`
A11	`02`	`1`		`@1 POWELL (Alissa M.)`
A11	`03`	`1`		`@1 KAIDANOVICH-BEILIN (Oksana)`
A11	`04`	`1`		`@1 SOCZYNSKA (Joanna K.)`
A11	`05`	`1`		`@1 ALSUWAIDAN (Mohammad)`
A11	`06`	`1`		`@1 WOLDEYOHANNES (Hanna O.)`
A11	`07`	`1`		`@1 KIM (Ashley S.)`
A11	`08`	`1`		`@1 GALLAUGHER (L. Ashley)`
A14	`01`			`@1 Department of Psychiatry, University of Toronto @2 Toronto, ON @3 CAN @Z 1 aut.`
A14	`02`			`@1 Department of Pharmacology, University of Toronto @2 Toronto, ON @3 CAN @Z 1 aut.`
A14	`03`			`@1 Mood Disorders Psychopharmacology Unit, University Health Network @2 Toronto, ON @3 CAN @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`04`			`@1 Institute of Medical Science, University of Toronto @2 Toronto, ON @3 CAN @Z 4 aut.`
A14	`05`			`@1 Samuel Lunenfeld Research Institute, Mount Sinai Hospital @2 Toronto, ON @3 CAN @Z 3 aut.`
A20				`@1 164-171`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18271 @5 354000173230240220`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 66 ref.`
A47	`01`	`1`		`@0 13-0122012`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Behavioural brain research`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.
C02	`01`	`X`		`@0 002A26C`
C03	`01`	`X`	`FRE`	`@0 Neuroprotection @5 01`
C03	`01`	`X`	`ENG`	`@0 Neuroprotection @5 01`
C03	`01`	`X`	`SPA`	`@0 Neuroprotección @5 01`
C03	`02`	`X`	`FRE`	`@0 Traitement @5 02`
C03	`02`	`X`	`ENG`	`@0 Treatment @5 02`
C03	`02`	`X`	`SPA`	`@0 Tratamiento @5 02`
C03	`03`	`X`	`FRE`	`@0 Trouble cognitif @5 03`
C03	`03`	`X`	`ENG`	`@0 Cognitive disorder @5 03`
C03	`03`	`X`	`SPA`	`@0 Trastorno cognitivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Trouble de l'humeur @5 04`
C03	`04`	`X`	`ENG`	`@0 Mood disorder @5 04`
C03	`04`	`X`	`SPA`	`@0 Trastorno humor @5 04`
C03	`05`	`X`	`FRE`	`@0 Cognition @5 05`
C03	`05`	`X`	`ENG`	`@0 Cognition @5 05`
C03	`05`	`X`	`SPA`	`@0 Cognición @5 05`
C03	`06`	`X`	`FRE`	`@0 Incrétine @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 Incretin @4 CD @5 96`
N21				`@1 098`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0122012 INIST
ET :	The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders
AU :	MCINTYRE (Roger S.); POWELL (Alissa M.); KAIDANOVICH-BEILIN (Oksana); SOCZYNSKA (Joanna K.); ALSUWAIDAN (Mohammad); WOLDEYOHANNES (Hanna O.); KIM (Ashley S.); GALLAUGHER (L. Ashley)
AF :	Department of Psychiatry, University of Toronto/Toronto, ON/Canada (1 aut.); Department of Pharmacology, University of Toronto/Toronto, ON/Canada (1 aut.); Mood Disorders Psychopharmacology Unit, University Health Network/Toronto, ON/Canada (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Institute of Medical Science, University of Toronto/Toronto, ON/Canada (4 aut.); Samuel Lunenfeld Research Institute, Mount Sinai Hospital/Toronto, ON/Canada (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Behavioural brain research; ISSN 0166-4328; Coden BBREDI; Irlande; Da. 2013; Vol. 237; Pp. 164-171; Bibl. 66 ref.
LA :	Anglais
EA :	Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.
CC :	002A26C
FD :	Neuroprotection; Traitement; Trouble cognitif; Trouble de l'humeur; Cognition; Incrétine
ED :	Neuroprotection; Treatment; Cognitive disorder; Mood disorder; Cognition; Incretin
SD :	Neuroprotección; Tratamiento; Trastorno cognitivo; Trastorno humor; Cognición
LO :	INIST-18271.354000173230240220
ID :	13-0122012

Links to Exploration step

Pascal:13-0122012

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders</title>
<author><name sortKey="Mcintyre, Roger S" sort="Mcintyre, Roger S" uniqKey="Mcintyre R" first="Roger S." last="Mcintyre">Roger S. Mcintyre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Powell, Alissa M" sort="Powell, Alissa M" uniqKey="Powell A" first="Alissa M." last="Powell">Alissa M. Powell</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaidanovich Beilin, Oksana" sort="Kaidanovich Beilin, Oksana" uniqKey="Kaidanovich Beilin O" first="Oksana" last="Kaidanovich-Beilin">Oksana Kaidanovich-Beilin</name>
<affiliation><inist:fA14 i1="05"><s1>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Soczynska, Joanna K" sort="Soczynska, Joanna K" uniqKey="Soczynska J" first="Joanna K." last="Soczynska">Joanna K. Soczynska</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Institute of Medical Science, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alsuwaidan, Mohammad" sort="Alsuwaidan, Mohammad" uniqKey="Alsuwaidan M" first="Mohammad" last="Alsuwaidan">Mohammad Alsuwaidan</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woldeyohannes, Hanna O" sort="Woldeyohannes, Hanna O" uniqKey="Woldeyohannes H" first="Hanna O." last="Woldeyohannes">Hanna O. Woldeyohannes</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kim, Ashley S" sort="Kim, Ashley S" uniqKey="Kim A" first="Ashley S." last="Kim">Ashley S. Kim</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gallaugher, L Ashley" sort="Gallaugher, L Ashley" uniqKey="Gallaugher L" first="L. Ashley" last="Gallaugher">L. Ashley Gallaugher</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0122012</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0122012 INIST</idno>
<idno type="RBID">Pascal:13-0122012</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000110</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders</title>
<author><name sortKey="Mcintyre, Roger S" sort="Mcintyre, Roger S" uniqKey="Mcintyre R" first="Roger S." last="Mcintyre">Roger S. Mcintyre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Powell, Alissa M" sort="Powell, Alissa M" uniqKey="Powell A" first="Alissa M." last="Powell">Alissa M. Powell</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaidanovich Beilin, Oksana" sort="Kaidanovich Beilin, Oksana" uniqKey="Kaidanovich Beilin O" first="Oksana" last="Kaidanovich-Beilin">Oksana Kaidanovich-Beilin</name>
<affiliation><inist:fA14 i1="05"><s1>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Soczynska, Joanna K" sort="Soczynska, Joanna K" uniqKey="Soczynska J" first="Joanna K." last="Soczynska">Joanna K. Soczynska</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Institute of Medical Science, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alsuwaidan, Mohammad" sort="Alsuwaidan, Mohammad" uniqKey="Alsuwaidan M" first="Mohammad" last="Alsuwaidan">Mohammad Alsuwaidan</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woldeyohannes, Hanna O" sort="Woldeyohannes, Hanna O" uniqKey="Woldeyohannes H" first="Hanna O." last="Woldeyohannes">Hanna O. Woldeyohannes</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kim, Ashley S" sort="Kim, Ashley S" uniqKey="Kim A" first="Ashley S." last="Kim">Ashley S. Kim</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gallaugher, L Ashley" sort="Gallaugher, L Ashley" uniqKey="Gallaugher L" first="L. Ashley" last="Gallaugher">L. Ashley Gallaugher</name>
<affiliation><inist:fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Behavioural brain research</title>
<title level="j" type="abbreviated">Behav. brain res.</title>
<idno type="ISSN">0166-4328</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Behavioural brain research</title>
<title level="j" type="abbreviated">Behav. brain res.</title>
<idno type="ISSN">0166-4328</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cognition</term>
<term>Cognitive disorder</term>
<term>Incretin</term>
<term>Mood disorder</term>
<term>Neuroprotection</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Neuroprotection</term>
<term>Traitement</term>
<term>Trouble cognitif</term>
<term>Trouble de l'humeur</term>
<term>Cognition</term>
<term>Incrétine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-4328</s0>
</fA01>
<fA02 i1="01"><s0>BBREDI</s0>
</fA02>
<fA03 i2="1"><s0>Behav. brain res.</s0>
</fA03>
<fA05><s2>237</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MCINTYRE (Roger S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>POWELL (Alissa M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KAIDANOVICH-BEILIN (Oksana)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SOCZYNSKA (Joanna K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ALSUWAIDAN (Mohammad)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WOLDEYOHANNES (Hanna O.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KIM (Ashley S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GALLAUGHER (L. Ashley)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacology, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Mood Disorders Psychopharmacology Unit, University Health Network</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institute of Medical Science, University of Toronto</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</s1>
<s2>Toronto, ON</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>164-171</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18271</s2>
<s5>354000173230240220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>66 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0122012</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Behavioural brain research</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A26C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Neuroprotection</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Neuroprotection</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Neuroprotección</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble cognitif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cognition</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cognition</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cognición</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Incrétine</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Incretin</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fN21><s1>098</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0122012 INIST</NO>
<ET>The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders</ET>
<AU>MCINTYRE (Roger S.); POWELL (Alissa M.); KAIDANOVICH-BEILIN (Oksana); SOCZYNSKA (Joanna K.); ALSUWAIDAN (Mohammad); WOLDEYOHANNES (Hanna O.); KIM (Ashley S.); GALLAUGHER (L. Ashley)</AU>
<AF>Department of Psychiatry, University of Toronto/Toronto, ON/Canada (1 aut.); Department of Pharmacology, University of Toronto/Toronto, ON/Canada (1 aut.); Mood Disorders Psychopharmacology Unit, University Health Network/Toronto, ON/Canada (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Institute of Medical Science, University of Toronto/Toronto, ON/Canada (4 aut.); Samuel Lunenfeld Research Institute, Mount Sinai Hospital/Toronto, ON/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Behavioural brain research; ISSN 0166-4328; Coden BBREDI; Irlande; Da. 2013; Vol. 237; Pp. 164-171; Bibl. 66 ref.</SO>
<LA>Anglais</LA>
<EA>Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1 ) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.</EA>
<CC>002A26C</CC>
<FD>Neuroprotection; Traitement; Trouble cognitif; Trouble de l'humeur; Cognition; Incrétine</FD>
<ED>Neuroprotection; Treatment; Cognitive disorder; Mood disorder; Cognition; Incretin</ED>
<SD>Neuroprotección; Tratamiento; Trastorno cognitivo; Trastorno humor; Cognición</SD>
<LO>INIST-18271.354000173230240220</LO>
<ID>13-0122012</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000110 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000110 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0122012
   |texte=   The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri